Paulo Amaral, MD @paulosiqamaral profile

Paulo Amaral, MD

@paulosiqamaral

Followers

386

Following

2K

Statuses

113

GU Oncology Clinical Fellow at Vanderbilt University | Former MedOnc Fellow and Assistant Professor at ICESP- University of Sao Paulo 🇧🇷 | ECFMG/FSMB

Nashville, TN

Joined August 2020

Don't wanna be here? Send us removal request.

Paulo Amaral, MD

@paulosiqamaral

4 days

TIVO is a efficacy approach in the refractory setting , this analysis along with TiNiVo-2 control arm reinforces it…unfortunately it is not widely available, and many pts face short list of treatment options

Miguel Zugman

@mzugman

4 days

4/7 OS was comparable in the ITT group (HR 0.89, 95% CI 0.70–1.14, p=0.35), but in CPI-pretreated patients, OS trended toward benefit with Tivo (HR 0.69, 95% CI 0.43–1.11, p=0.0992). Responders with Tivo had a median DOR of 22 mo (20.3 in CPI-exposed) vs 5.7 mo with Sora.

1

0

4

Paulo Amaral, MD

@paulosiqamaral

1 month

RT @urotoday: #ProstateCancer diversity revealed: AR and neuroendocrine signatures. @YuWeiChenMD @UCSDCancer joins @CaPsurvivorship @DanaFa…

0

7

0

Paulo Amaral, MD

@paulosiqamaral

2 months

RT @LauraBukavinaMD: Serial ctDNA monitoring in met RCC Patients with serial ctDNA - or clearance had a 3.2x ⬇️ risk of progression during…

0

14

0

Paulo Amaral, MD

@paulosiqamaral

2 months

RT @kidneycan: $0 ➡️ $285 MILLION for #KidneyCancer research in 8 years! That is the power of advocacy. Join our advocacy team and be p…

0

6

0

Paulo Amaral, MD

@paulosiqamaral

2 months

RT @oncodaily: The role of belzutifan in treating rare mutation VHL congenital-related polycythemia - @katy_beckermann @paulosiqamaral h…

0

2

0

Paulo Amaral, MD

@paulosiqamaral

2 months

Thrilled to highlight this wise choice of using HIF inhibition as a therapeutic advantage in managing VHL-related polycythemia! Thanks @katy_beckermann for this leading this!

Katy Beckermann

@katy_beckermann

2 months

Excited to share this case report led by the brilliant @paulosiqamaral ! It highlights the role of belzutifan in treating rare mutation VHL congenital-related polycythemia, showcasing its efficacy and safety.🌟 #GUOncology #VHL

0

18

Paulo Amaral, MD

@paulosiqamaral

4 months

RT @tompowles1: Voluntary withdrawal of sacituzumab govitecan in pretreated advanced bladder cancer occurred today. Accelerated approval re…

0

60

0

Paulo Amaral, MD

@paulosiqamaral

4 months

RT @BrunoLimaMDPhD: Nobel Prize in Chemistry this year goes to a @VanderbiltU alumni

0

1

0

Paulo Amaral, MD

@paulosiqamaral

4 months

RT @Uromigos: We discussed the role of ipi/nivo after PD1-based therapy. Several trials have added ipilimumab upon progression/lack of resp…

0

12

0

Paulo Amaral, MD

@paulosiqamaral

4 months

RT @VandyFootball: ROLL DORES ROLL

0

1K

0

Paulo Amaral, MD

@paulosiqamaral

4 months

#UromigosLive24

0

Paulo Amaral, MD

@paulosiqamaral

5 months

@JVentoMD @alantanmd @brian_rini @katy_beckermann @catherine_fahey @NBDavisMD @Uromigos @UroCancerMD

0

Paulo Amaral, MD

@paulosiqamaral

5 months

@chadihc98 Congrats Chadi!!!

1

0

1

Paulo Amaral, MD

@paulosiqamaral

5 months

Besides its primary EP, PEACE-3 highlights the importance of BPA in bone-mCRPC

0

4

Paulo Amaral, MD

@paulosiqamaral

5 months

RT @tompowles1: Nectin-4 is the target for Enfortumab Vedotin and is widely expressed in UC (median 275/300) . EV302 is 1st randomised tria…

0

56

0

Paulo Amaral, MD

@paulosiqamaral

5 months

TiNivo-2 also reinforces efficacy of Tivo in refractory mRCC: 🔵Tivo-3, 20% (~45 pts) prior-IO, w/ 18% OR and PFS of 7.3 mo 🔵 TiNivo-2, 100% (~170 pts) prior IO, w/ 20% OR PFS 7.4 mo 🔵 Tivo has a diff tox & good tolerance, 🟡🇧🇷health agency should consider its approval.

0

2

Paulo Amaral, MD

@paulosiqamaral

5 months

@JVentoMD 👏🏼👏🏼👏🏼

0

2

Paulo Amaral, MD

@paulosiqamaral

5 months

Unfortunately, many Brazilian friends are no longer able to read this message…

0

1